24Mar 2023
Extending the dosing interval of COVID-19 vaccination leads to higher rates of seroconversion in people living with HIV

Extending the dosing interval of COVID-19 vaccination leads to higher rates of seroconversion in people living with HIV

The study investigated the neutralizing antibody (NAb) responses to the third dose of the COVID-19 vaccine in people living with HIV (PLWH) with different inoculation intervals. The results showed that a longer interval between the second and third doses elicited better NAb responses in PLWH. The study also identified independent risk factors for NAb seroconversion failure, including vaccination interval and lymphocyte counts. Furthermore, the study found that post-vaccination seroconversion reduced the number of symptoms induced by the Omicron variant in PLWH. However, none of the participants, including HCs or PLWH, could mount a NAb response against the Omicron BA.5.2 variant.

  • #family health

Like

Save

Share